Virlaza® mission
Virlaza® contributes to improving the symptoms associated with SARS-CoV2 (COVID-19), pneumonia, influenza, and other acute viral diseases, as follows:
reduced risk of ARDS development (the main cause of death from respiratory diseases) brought about by the body's response to coronavirus (COVID-19)
body temperature regulation
amelioration of respiratory disorders resulting from acute viral diseases
relief of side effects following vaccination
relief of other symptoms caused by virus diseases
reduction of the inflammation that causes a cytokine storm
relief of hypoxic state associated with coronavirus and pneumonic fever
Patients, diagnosed with COVID-19 and having taken Virlaza®, have observed the following changes:
fever reduction
improved breathing
reduced headache
pain relief in muscles and vessels
better blood oxygenation
improved sleep quality
improvement of general state, reduced sweating
Ingredients
The remedy is completely organic and its composition contains unique plant extracts fortified by micronutrients.
The product does not contain GMO.
Ingredients: complex of terpenoids (monoterpenes, sesquiterpenes), flavonoids, phenolic compounds from extracts of: dianthus (Caryophylli flori), eucalyptus (Eucalypti aetheroleum), pine (Pini sylvestris), basil (Folium Ocimi Sancti), and salvia (Salviae officinalis foli). Minerals: selenium, zinc. Contains ethyl alcohol.
Active ingredients: -eugenol, β-caryophyllen, -caryophyllen; 1.8-cineole; α-and β –pinene, γ-terpinene, α- terpinene, camphene, limonene, borneol, estragole (methyl chavicol), ocimene, methyleugenol; humulene, bornyl acetate, linalyl acetate, linalool, sclareol, α-terpineol; terpenoid compounds (monoterpene, sesquiterpene, iridoid), eugenol, cineole, ocimene, pinene, zinc, selenium..
Ingredients: complex of terpenoids (monoterpenes, sesquiterpenes), flavonoids, phenolic compounds from extracts of: dianthus (Caryophylli flori), eucalyptus (Eucalypti aetheroleum), pine (Pini sylvestris), basil (Folium Ocimi Sancti), and salvia (Salviae officinalis foli). Minerals: selenium, zinc. Contains ethyl alcohol.
Active ingredients: -eugenol, β-caryophyllen, -caryophyllen; 1.8-cineole; α-and β –pinene, γ-terpinene, α- terpinene, camphene, limonene, borneol, estragole (methyl chavicol), ocimene, methyleugenol; humulene, bornyl acetate, linalyl acetate, linalool, sclareol, α-terpineol; terpenoid compounds (monoterpene, sesquiterpene, iridoid), eugenol, cineole, ocimene, pinene, zinc, selenium..
Evidence indicates that Virlaza®️ may revolutionize the treatment of a wide range of immunological diseases.
The terpenoids and terpenes contained in Virlaza® are known for their strong ability to protect cells from the most severe and adverse effects.
The terpenoids and terpenes contained in Virlaza® are known for their strong ability to protect cells from the most severe and adverse effects.
Virlaza® effects
Balancing of the body's immune system and preventing immunity overreaction (a cytokine storm), with simultaneous regulation of anti-inflammatory mechanisms, which may significantly improve recovery time.
Studies on Virlaza® effects against pneumonia have shown significantly reduced inflammation, airway hyperresponsiveness, airway remodeling, and relief from compromised lung mechanics and oxidative stress.
The Libi Pharm team is actively engaged in meeting the regulatory requirements in order to register Virlaza® as a medication.
Due to the extraordinary demand and to ensure immediate access to the product, the decision has now been made to release Virlaza® to the market under dietary supplement regulations.
Due to the extraordinary demand and to ensure immediate access to the product, the decision has now been made to release Virlaza® to the market under dietary supplement regulations.
Virlaza® is a copyright-protected product designed in 2020.
The research, conducted at the Institute of São Paulo, Pulmonology Division, has shown that Virlaza® significantly inhibits the inflammation in the lung tissue induced by SARS-CoV2 (COVID-19). Virlaza® inhibits the synthesis and secretion of proinflammatory cytokines such as IL-1β, IL-6, IL-8, and TNF-α, and stimulates the secretion of anti-inflammatory cytokines such as IL-1RA. Research has also shown that Virlaza® effectively reduces fibroblasts (scar tissue cells) activation and proliferation.
Target patients/conditions:
Patients suffering from COVID-19, influenza, and ARVI
Patients suffering from pneumonia and ARDS
Patients with oxidative stress
Patients in the recovery/healing phase from COVID-19 and influenza
Severe/marked side effects after COVID-19 vaccination
Severe fever in inflammatory conditions
MODS (multiple organ dysfunction syndrome) in patients with COVID-19, pneumonia, influenza
Evidence indicates that Virlaza®️ may revolutionize the treatment of a wide
range of immunological diseases.
The terpenoids and terpenes
contained in Virlaza® are known for
their strong ability to protect cells
from the most severe and adverse effects.
range of immunological diseases.
The terpenoids and terpenes
contained in Virlaza® are known for
their strong ability to protect cells
from the most severe and adverse effects.
Studies on Virlaza® effects against pneumonia have shown significantly reduced inflammation, airway hyperresponsiveness, airway
remodeling, and relief from compromised lung mechanics and oxidative stress.
remodeling, and relief from compromised lung mechanics and oxidative stress.
For ARDS (Acute Respiratory Distress Syndrome)
Acute respiratory distress syndrome (ARDS) is one of the major problems in patients suffering from COVID-19 and pneumonia. It is also the leading cause of death from COVID-19.
Used as an aid to prescribed medicines, Virlaza® has shown to be potentially highly effective in conditions associated with ARDS.
The product may significantly alleviate the condition and reduce the symptoms associated with COVID-19, pneumonia, and influenza, shorten disease progression and prevent further complications.
Used as an aid to prescribed medicines, Virlaza® has shown to be potentially highly effective in conditions associated with ARDS.
The product may significantly alleviate the condition and reduce the symptoms associated with COVID-19, pneumonia, and influenza, shorten disease progression and prevent further complications.
Recommendations for use
Failure to comply with the recommendations leads to a decreased efficacy of the remedy.
Warning!
Shake before each use!
Shake before each use!
Attention!
Take at least one hour before meals or 3 hours after meals.
Take at least one hour before meals or 3 hours after meals.
Drip into a glass; combine with 50-100 ml of citrus juice or water.
It is advised to take the product for at least 4 days to improve the condition.
Adults with body weight up to 70 kg (154 lb):
First 4 days:
60 drops in the morning. 30 drops every 3 hours throughout the day.
60 drops before bedtime.
Starting from day 5: 30 drops, 2 times a day.
60 drops in the morning. 30 drops every 3 hours throughout the day.
60 drops before bedtime.
Starting from day 5: 30 drops, 2 times a day.
< 70 kg
Adults with body weight over 70 kg (154 lb):
First 4 days:
90 drops in the morning. 30 drops every 3 hours throughout the day.
90 drops before bedtime.
Starting from day 5: 30 drops, 2 times a day.
90 drops in the morning. 30 drops every 3 hours throughout the day.
90 drops before bedtime.
Starting from day 5: 30 drops, 2 times a day.
< 70 kg
Adults with high fever and severe disease:
First 4 days:
90 drops in the morning. 50 drops every 3 hours throughout the day.
90 drops before bedtime.
Starting from day 5: 30 drops, 2 times a day.
90 drops in the morning. 50 drops every 3 hours throughout the day.
90 drops before bedtime.
Starting from day 5: 30 drops, 2 times a day.
> 38.8 °C
Children aged 6-12 years:
First 4 days:
30 drops a day.
From day 5: 10 drops, 2 times a day.
30 drops a day.
From day 5: 10 drops, 2 times a day.
6-12
years old
years old
As a preventive measure:
Adults: 30 drops per day. Children: 10 drops per day.
Duration: 3-4 weeks every 6 months.
Duration: 3-4 weeks every 6 months.
6-∞
1 bottle - 30 ml contains approximately 1000 drops.
Although your condition may improve within a short time with the use of the Virlaza®, it is recommended to continue the use of the product for 10-14 days, counting from the first day and monitoring the general condition.
This can lead to a better improvement of residual symptoms of the disease.
This can lead to a better improvement of residual symptoms of the disease.
Contraindications:
Children under six, individual intolerance, pregnancy, oncology treatment, taking of immunosuppressant drugs, allergy to the ingredients.
Side effects:
Individual intolerance to the ingredients.
Storage:
Store in a dark, dry place at a temperature between +4 C and +26°C (from 39°F to 78°F).
Virlaza® scope of application:
This product can be used to boost immunity and help prevent various diseases.
It can be used as an effective measure for recovery from diseases of various etiologies, including those caused by SARS-CoV2.
As a measure to reduce symptoms caused by side effects following COVID-19 vaccination.
About the manufacturer
LIBI PHARM is a pioneering, privately owned Israeli drug and medical device development company that has created the patented, innovative product Virlaza®️, which could be a breakthrough in the treatment of a number of diseases characterized by acute respiratory failure, including those caused by the COVID-19 coronavirus, as well as a number of immunological disorders.
Documents
New therapy method COVID 19
The Libi Pharm team is actively engaged in meeting the regulatory requirements in order to register Virlaza® as a
medication.
Due to the extraordinary demand and to ensure immediate access to the product, the decision has now been made to release
Virlaza® to the market under dietary supplement regulations.
medication.
Due to the extraordinary demand and to ensure immediate access to the product, the decision has now been made to release
Virlaza® to the market under dietary supplement regulations.
Development and research of the company "LibiPharm" - "LibiPharm" Israel.
© 2023 Calpton SIA. All rights reserved.
We accept
